DK0493468T3 - Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister - Google Patents

Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister

Info

Publication number
DK0493468T3
DK0493468T3 DK90914257.2T DK90914257T DK0493468T3 DK 0493468 T3 DK0493468 T3 DK 0493468T3 DK 90914257 T DK90914257 T DK 90914257T DK 0493468 T3 DK0493468 T3 DK 0493468T3
Authority
DK
Denmark
Prior art keywords
histamine
subject
agent
receptor agonists
receptor
Prior art date
Application number
DK90914257.2T
Other languages
English (en)
Inventor
Jan Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Syntello Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Inc filed Critical Syntello Inc
Application granted granted Critical
Publication of DK0493468T3 publication Critical patent/DK0493468T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK90914257.2T 1989-09-19 1990-09-19 Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister DK0493468T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19

Publications (1)

Publication Number Publication Date
DK0493468T3 true DK0493468T3 (da) 1996-08-26

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90914257.2T DK0493468T3 (da) 1989-09-19 1990-09-19 Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister

Country Status (12)

Country Link
US (1) US5348739A (da)
EP (1) EP0493468B1 (da)
JP (1) JP2845622B2 (da)
KR (1) KR100195392B1 (da)
AT (1) ATE136786T1 (da)
AU (1) AU640954B2 (da)
CA (1) CA2066728C (da)
DE (1) DE69026620T2 (da)
DK (1) DK0493468T3 (da)
ES (1) ES2087163T3 (da)
NO (1) NO921050D0 (da)
WO (1) WO1991004037A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5533094A (en) * 1992-11-27 1994-06-22 Wellcome Foundation Limited, The Enzyme inhibitors
JPH10504304A (ja) * 1994-08-08 1998-04-28 マキシム ファーマシューティカルズ，インコーポレイテッド ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
EP1107784A2 (en) * 1998-08-24 2001-06-20 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4?+ and cd8?+ ) using an h 2? receptor agonist and other t-cell activating agents
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
AU779215B2 (en) * 1999-07-16 2005-01-13 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
WO2003082081A2 (en) * 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
WO2006039545A2 (en) * 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
KR20070116011A (ko) 2005-02-25 2007-12-06 이노텍 파마슈티컬스 코포레이션 테트라사이클릭 아미노 및 카복사미도 화합물 및 이의 이용방법
RU2008110955A (ru) 2005-08-24 2009-09-27 Инотек Фармасьютикалз Корпорейшн (Us) Инденоизохинолиноновые аналоги и способы их применения
WO2008106619A2 (en) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
EP2419099A2 (en) * 2009-04-16 2012-02-22 Epicept Corporation Composition and use of n-alpha-methylhistamine
JP6051378B2 (ja) * 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
CA3068587A1 (en) * 2017-06-29 2019-01-03 Immune Pharmaceuticals, Inc. Methods of delaying and preventing acute myeloid leukemia relapse
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
DE69026620T2 (de) 1996-10-02
CA2066728A1 (en) 1991-03-20
KR100195392B1 (ko) 1999-06-15
KR920703078A (ko) 1992-12-17
WO1991004037A1 (en) 1991-04-04
JPH05504548A (ja) 1993-07-15
EP0493468A1 (en) 1992-07-08
ATE136786T1 (de) 1996-05-15
EP0493468B1 (en) 1996-04-17
DE69026620D1 (de) 1996-05-23
NO921050L (no) 1992-03-18
ES2087163T3 (es) 1996-07-16
US5348739A (en) 1994-09-20
AU6419190A (en) 1991-04-18
NO921050D0 (no) 1992-03-18
CA2066728C (en) 2001-12-25
JP2845622B2 (ja) 1999-01-13
AU640954B2 (en) 1993-09-09

Similar Documents

Publication Publication Date Title
DK0493468T3 (da) Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister
Goldstein et al. The role of interferon in cancer therapy: a current perspective
Rosenberg et al. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes
ES2187519T3 (es) 7-halogeno-y 7beta,8beta-metano-taxoles, uso antineoplasico y composiciones farmaceuticas que los contienen.
DK0565587T3 (da) Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation.
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
DK0683762T3 (da) Acylfulven-analoger som antitumormidler
EP0210753A3 (en) Anti-tumor medicament
PH13417A (en) Thiourea and guanidine derivative having actively as hestamine h2 receptor antagonists and pharmaceuas histamine h2 receptor artagonists and pharmaceutical composition
Shimizu et al. Effects of a single injection of anti‐asialo GM1 serum on natural cytotoxicity and the growth of a regressive colonic tumor in syngeneic rats
Baxevanis et al. Induction of lymphokine-activated killer activity in mice by prothymosin α
Choudhury et al. Interferons and interleukins in metastatic renal cell carcinoma
Dillman et al. Phase I trials of thymosin fraction 5 and thymosin α1
Alpaugh et al. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon
Maeda et al. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma
ES2039236T3 (es) Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral.
Betzler et al. Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up
Wang et al. Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin
Rochlitz et al. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors
Gold et al. Autolymphocyte therapy—I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes
Robins Purine nucleoside 3′, 5′-cyclic monophosphates as hormonal modulators of cellular proliferation, metastases and lymphocyte response
Puri et al. In vivo treatment with interferon causes augmentation of IL‐2 induced lymphokine‐activated killer cells in the organs of mice
Voltchek et al. Comparative study of the cytostatic effects of Oliphen and Ukrain
Hokland et al. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial
Allavena et al. Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells